Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.61 |
| ▸ | CNR2 | P34972 | 15/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5146725 | 0.91 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL5147420 | 0.86 | CNR1 (0.71) | CNR1CNR2 | |
| SCHEMBL5146878 | 0.86 | CNR1 (0.74) | CNR1CNR2 | |
| SCHEMBL5146661 | 0.84 | CNR1 (0.71) | CNR1CNR2 | |
| SCHEMBL5147398 | 0.79 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL5145119 | 0.79 | CNR1 (0.76) | CNR1CNR2 | |
| SCHEMBL5145211 | 0.79 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL5147325 | 0.78 | CNR1 (0.73) | CNR1CNR2 | |
| SCHEMBL5584867 | 0.78 | CNR1 (0.50) | CNR1CNR2S1PR1ADAMTS5MMP2 | |
| SCHEMBL14512668 | 0.76 | CNR1 (1.00) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663113-A4 | SUBSTITUTED SULFONAMIDES | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | claimed |
| US-20070105914-A1 | Substituted sulfonamides | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | claimed |
| CN-1956949-A | Substituted sulfonamides | MERCK & CO INC (US) | 2007-05-02 | — | — | CN | claimed |
| EP-1663113-A2 | SUBSTITUTED SULFONAMIDES | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005027837-A2 | SUBSTITUTED SULFONAMIDES | MERCK & CO., INC. (US) | 2005-03-31 | — | — | WO | claimed |
| US-20070105914-A1 | Substituted sulfonamides | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | disclosed |
| US-20070105914-A1 | Substituted sulfonamides | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | disclosed |
| US-20070105914-A1 | Substituted sulfonamides | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105914-A1 | Substituted sulfonamides | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885S1PR1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.